PMID- 16480575
OWN - NLM
STAT- MEDLINE
DCOM- 20061020
LR  - 20150313
VI  - 25
IP  - 2
DP  - 2006 Feb
TI  - [Killing activity of cytotoxic T lymphocytes stimulated by dendritic cell vaccine 
      loaded with autologous cervical cancer antigen].
PG  - 143-7
AB  - BACKGROUND & OBJECTIVE: Dendritic cells (DCs), the strongest antigen-presenting 
      cells (APCs), can present antigens to T lymphocytes in vivo and in vitro, and 
      induce cytotoxic T lymphocyte (CTL) reaction. This study was designed to 
      investigate the killing activity of CTLs stimulated by Dcs loaded with autologous 
      cervical cancer antigen in vitro. METHODS: Tumor antigens were made from 
      frozen-thawed cervical cancer cells from patients after operation. DCs were 
      isolated from peripheral blood mononuclear cells of patients with cervical 
      cancer, cultured with granulocyte-macrophage colony-stimulating factor (GM-CSF) 
      and interleukin-4 (IL-4), loaded with tumor antigen to prepare DC vaccine, and 
      used to stimulate autologous T lymphocytes to prepare antigen-specific CTLs. The 
      killing activities of CTLs on autologous cervical cancer cells and HeLa, HepG2, 
      MCF7, A549, and MGC803 cells were observed. RESULTS: CTLs stimulated by the DC 
      vaccine had high killing activity on autologous cervical cancer cells, with 
      killing rates of 79.32%-89.27% which were obviously higher than that of 
      lymphokine-activated killing cells (t> or =2.89, P<0.05). The killing activity of 
      CTLs was significantly weaker on HeLa cells (40.35%-58.09%) than on autologous 
      cervical cancer cells (t> or =2.97, P<0.05). The specific CTLs had no obvious 
      killing activity on HepG2, MCF7, A549, and MGC803 cells. CONCLUSIONS: CTLs 
      stimulated by autologous cervical cancer antigen-loaded DCs have highly efficient 
      and specific immune activity on autologous cervical cancer cells. It may be used 
      in biotherapy for cervical cancer.
FAU - Zhou, Chang-Ju
AU  - Zhou CJ
AD  - Department of Obstetrics and Gynecology, The Third Xiangya Hospital, Central 
      South University, Changsha, Hunan 410013, P. R. China. 8808816@163.com
FAU - Ma, Wei
AU  - Ma W
FAU - Zhou, Jian-Da
AU  - Zhou JD
FAU - Zhao, Yong-Xiang
AU  - Zhao YX
FAU - Xie, Hui-Qing
AU  - Xie HQ
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Ai Zheng
JT  - Ai zheng = Aizheng = Chinese journal of cancer
JID - 9424852
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 207137-56-2 (Interleukin-4)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Antigens, Neoplasm/immunology
MH  - Cancer Vaccines/*pharmacology
MH  - Carcinoma, Squamous Cell/*immunology/pathology
MH  - Cytotoxicity, Immunologic
MH  - Dendritic Cells/cytology/*immunology
MH  - Female
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology
MH  - Humans
MH  - Interleukin-4/pharmacology
MH  - Lymphocyte Activation
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Tumor Cells, Cultured
MH  - Uterine Cervical Neoplasms/*immunology/pathology
EDAT- 2006/02/17 09:00
MHDA- 2006/10/21 09:00
CRDT- 2006/02/17 09:00
PHST- 2006/02/17 09:00 [pubmed]
PHST- 2006/10/21 09:00 [medline]
PHST- 2006/02/17 09:00 [entrez]
AID - 1000467X2006020143 [pii]
PST - ppublish
SO  - Ai Zheng. 2006 Feb;25(2):143-7.